Endoxifen

Drug Profile

Endoxifen

Alternative Names: 4-Hydroxy-N-desmethyltamoxifen; Z-endoxifen

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intas Pharmaceuticals; Jina Pharmaceuticals
  • Developer Jina Pharmaceuticals; National Cancer Institute (USA)
  • Class Antineoplastics; Methylamines; Phenyl ethers; Stilbenes
  • Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer

Most Recent Events

  • 26 Oct 2017 National Cancer Institute plans a phase I trial for Breast cancer (Neoadjuvant therapy) in USA in April 2018 (NCT03317405)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Breast-cancer(In volunteers) in India (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Breast-cancer in Unknown (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top